Literature DB >> 1121143

Sympathetic nervous activity in renal and DOC hypertensive rats.

J Iriuchijima, S Mizogami, H Sokabe.   

Abstract

The sympathetic tone of the splanchnic nerve was quantified in renal and deoxycorticosterone (DOC) hypertensive rats under pentobarbital anesthesia by measuring equivalent stimulation frequency (ESF). ESF is the frequency of stimulus to the peripheral cut end of the nerve required to restore the preseverance level of arterial pressure. It is assumed to represent the average discharge rate of the nerve before severance. ESF was markedly increased in DOC hypertension 2 weeks after initiation of the DOC-salt treatment. It was relatively decreased after 10 weeks, but was still higher than in the controls. In renal hypertension (clipping of the left renal artery), ESF was decreased considerably 2 weeks and slightly 10 weeks after clipping. When the contralateral kidney had been removed simultaneously with clipping (clip plus uninephrectomy, ESF was not significantly changed. It is suggested that the sympathetic nervous system participates greatly in the pathogenesis of DOC hypertension but not of renal hypertension.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1121143     DOI: 10.1536/ihj.16.36

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  3 in total

1.  Antioxidant treatment restores prejunctional regulation of purinergic transmission in mesenteric arteries of deoxycorticosterone acetate-salt hypertensive rats.

Authors:  S L Demel; H Dong; G M Swain; X Wang; D L Kreulen; J J Galligan
Journal:  Neuroscience       Date:  2010-04-14       Impact factor: 3.590

2.  Mild DOCA-salt hypertension: sympathetic system and role of renal nerves.

Authors:  Sachin S Kandlikar; Gregory D Fink
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-25       Impact factor: 4.733

3.  Impaired purinergic neurotransmission to mesenteric arteries in deoxycorticosterone acetate-salt hypertensive rats.

Authors:  Stacie L Demel; James J Galligan
Journal:  Hypertension       Date:  2008-07-07       Impact factor: 10.190

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.